Alnylam Stock Is Dropping on Surprising FDA Rejection

France Nouvelles Nouvelles

Alnylam Stock Is Dropping on Surprising FDA Rejection
France Dernières Nouvelles,France Actualités
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 35 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 97%

Drugmaker Alnylam wanted to expand approval of its drug Onpattro, but the Food and Drug Administration rejected the application even after an outside...

The Food and Drug Administration delivered a surprising rejection on Monday of an approval application from the drugmaker Alnylam Pharmaceuticals, sending shares of the biotech down 7% in morning trading to $164.62.

An approval in the cardiomyopathy indication could have meant a significant boost to Alnylam sales, which were $1 billion in 2022. Far more patients suffer from ATTR with cardiomyopathy than with polyneuropathy, though questions about Onpattro’s efficacy in the indication have dogged the program, and analysts had muted hopes for the drug’s commercial uptake.

On Monday, Alnylam CEO Yvonne Greenstreet said on an investor call that the company was surprised by the rejection. “The advisory committee voted in favor of patisiran,” Greenstreet said, using the drug’s generic name. “We’re disappointed that the FDA’s decision was not in alignment with the committee’s position.”

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

MarketWatch /  🏆 3. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

1 Stock to Buy, 1 Stock to Sell This Week: JPMorgan Chase, Citigroup1 Stock to Buy, 1 Stock to Sell This Week: JPMorgan Chase, CitigroupStocks Analysis by Investing.com (Jesse Cohen) covering: Citigroup Inc, JPMorgan Chase & Co, JP Morgan Chase & Co, Citigroup Inc. Read Investing.com (Jesse Cohen)'s latest article on Investing.com
Lire la suite »

Alnylam to scrap sNDA for patisiran after receiving FDA complete response letterAlnylam to scrap sNDA for patisiran after receiving FDA complete response letterCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Lire la suite »

RFK Jr. Dropping Dem Campaign to Run Independent or Third PartyRobert F. Kennedy Jr. is expected to announce Monday he will drop his Democrat bid for president and run as an independent or third-party candidate, adding a new wrinkle to a 2024 race currently heading toward a rematch between President Joe Biden and former President Donald Trump.
Lire la suite »

Red Lantern Kills, Siryn Screams, & Jean Grey Attacks Emma Frost in Jaw-Dropping Cosplay ShowcaseRed Lantern Kills, Siryn Screams, & Jean Grey Attacks Emma Frost in Jaw-Dropping Cosplay ShowcasePhotographer Pat Loika has brought together some stunning cosplays in comic-inspired images, many of which replicate iconic comic covers.
Lire la suite »

Surprising Tectonic Discovery: Geologist Unexpectedly Finds Remnants of a Lost Mega-PlateSurprising Tectonic Discovery: Geologist Unexpectedly Finds Remnants of a Lost Mega-PlateScience, Space and Technology News 2023
Lire la suite »

Survival Secrets: Surprising Traits of Mammals That Survive Mass ExtinctionsSurvival Secrets: Surprising Traits of Mammals That Survive Mass ExtinctionsScience, Space and Technology News 2023
Lire la suite »



Render Time: 2025-02-28 23:34:05